You just read:

Novartis breakthrough therapy LEE011 (ribociclib) plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

News provided by

Novartis Pharmaceuticals Corporation

Oct 08, 2016, 08:00 ET